Youssef O.
- Country
- France
- Department
- Pneumology
Research Overview
- Phase II Study of Tarlatamab in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and ECOG Performance Status 2
- Evaluation of Adagrasib Dosing Regimens in Previously Treated KRAS G12C-Mutant Non-Small Cell Lung Cancer Patients
- An open-label, multicenter, Phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor Tuvusertib (M1774) in combination with cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies (DDRiver NSCLC 322)
Data & Insights
Has run more than one trial at 273 of 502 partner sites.
Specializations
Lung Cancer Specialization
The investigator demonstrates extensive expertise in treating various forms of lung cancer, with particular focus on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their research encompasses both early-stage and advanced disease states.
- Advanced NSCLC Treatment
- Limited-Stage SCLC Management
- EGFR-Mutant NSCLC
Immunotherapy Applications
The investigator specializes in immunotherapy approaches for cancer treatment, particularly focusing on consolidation therapy and novel therapeutic combinations. Their work includes evaluation of various immunological agents in different treatment settings.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Maintenance Treatment Strategies
Targeted Therapies
The investigator works with precision medicine approaches, focusing on specific molecular targets and genetic mutations in cancer treatment. Their research includes evaluation of novel targeted agents for specific patient populations.
- EGFR Mutation Treatment
- ALK-Rearrangement Therapy
- KRAS G12C Targeting
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.